Here are 1-2 brief analogies for Skye Bioscience:

• Essentially, it's like GW Pharmaceuticals (a pioneer in cannabinoid-based medicines) but dedicated entirely to developing treatments for eye diseases.
• Think of it as a specialized Alcon (a major eye care company), but one that focuses purely on discovering and developing new cannabinoid-based drugs for a range of ophthalmic conditions.

• SBI-100: A cannabinoid-based molecule in Phase I trials for the treatment of glaucoma and ocular hypertension.
• SBI-200: A cannabinoid-based molecule in preclinical trials to treat and manage various eye diseases.

Based on the provided company description, Skye Bioscience, Inc. (SKYE) is a biopharmaceutical company primarily engaged in the discovery, development, and preclinical/clinical trials of cannabinoid-based molecules. Their lead product candidate, SBI-100, is in Phase I trials, and SBI-200 is in preclinical trials. At this stage of development, the company does not have commercially approved products available for sale.

Therefore, Skye Bioscience does not currently have major customers, either other companies or individuals, as they are focused on research and development rather than product commercialization and sales.

Punit Dhillon, President, Chief Executive Officer, and Principal Accounting Officer

Punit Dhillon was appointed CEO in August 2020. Effective February 20, 2026, he also assumed the role of Principal Accounting Officer. He is the co-founder and former President and CEO of OncoSec Medical Inc. (NASDAQ: ONCS), a biotechnology company pioneering new technologies to fight cancer, where he raised over $200M and established partnerships with Merck and Genentech. Prior to Skye, he served as a managing director of a private San Diego-based pharmaceutical company, where he launched an Asia-focused licensing business unit evaluating opportunities in Korea, China, Japan, and the US, and completed a partnership with BMS. He was formerly a director of the Emerald group of companies with responsibility for private equity investments, operations, and business development. As Vice President, Finance and Operations, at Inovio Pharmaceuticals, he completed licensing deals with Merck, Wyeth (now Pfizer), and Roche. Mr. Dhillon co-founded YELL Canada, an accelerator program for high school students interested in business and entrepreneurship. He has a 20-year track record as an executive and investor in the life sciences industry, focusing on early-stage biotechs from start-up through clinical proof-of-concept, raising over $500 million in capital and establishing multiple pharmaceutical partnerships.

Tu Diep, Chief Operating Officer

Tu Diep was appointed Chief Operating Officer in January 2025, having previously served as Chief Development Officer (January 2022–December 2024) and Senior Vice President of Development (October 2020–January 2022). He brings more than 15 years of scientific and clinical research experience to Skye Bioscience. Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc. (now Sophiris Bio Inc.), a company developing highly targeted, minimally invasive treatments, where he gained extensive experience in preclinical research and development, clinical protocol development and design, clinical operations, and biologics manufacturing. While at Protox, he was integrally involved in solidifying a $75 million regional partnership with a Japanese pharmaceutical company and securing a $35 million investment from the private equity firm Warburg Pincus. In 2011, Mr. Diep joined OncoSec Medical Inc. as a founding employee. He led the development and initiation of the company's lead program, tavokinogene telsaplasmid (TAVO), and spearheaded a key clinical collaboration with Merck. Following OncoSec, he held positions as VP, Strategic Operations for Emerald Health Sciences (a global cannabis company), and Director, Business Process for Element Biosciences (a private next-generation sequencing start-up).

Chris Twitty, PhD, Chief Scientific Officer

Chris Twitty serves as the Chief Scientific Officer at Skye Bioscience.

Puneet S. Arora, M.D., M.S., F.A.C.E., Chief Medical Officer

Puneet S. Arora was appointed as the Chief Medical Officer for Skye Bioscience. He brings extensive experience in clinical trials and regulatory submissions.

For Skye Bioscience (SKYE), the key risks to the business are primarily centered around the inherent challenges of clinical-stage biopharmaceutical development, its financial solvency as a pre-revenue company, and the intense competitive landscape of its target market.

1. Clinical Trial Failure and Regulatory Uncertainty

   As a biopharmaceutical company without commercialized products, Skye Bioscience's valuation and future depend almost entirely on the successful outcome of its clinical trials and subsequent regulatory approvals. The company has already experienced a significant setback with the discontinuation of its SBI-100 Ophthalmic Emulsion program for glaucoma, which failed to meet its primary endpoint in a Phase 2a clinical trial. Skye has since pivoted its full clinical development resources to nimacimab, a CB1 inhibitor primarily for obesity, which is currently in Phase 2 trials. Nimacimab itself has faced challenges, with a mid-stage clinical trial for weight loss as a monotherapy not demonstrating significant improvement, leading to a substantial drop in the company's stock value. Although nimacimab showed promise in combination therapy, the path through Phase 2 and potentially Phase 3 trials is fraught with uncertainties regarding efficacy, patient retention, and safety. Only a small percentage of drugs entering Phase 1 ultimately achieve market approval (approximately 9.6%), highlighting the high attrition rate in drug development. Furthermore, navigating FDA requirements, especially for combination therapies, poses an ongoing regulatory hurdle.

2. Financial Health and Funding Risk

   Skye Bioscience is a pre-revenue company, meaning it currently generates no income from product sales, and its operations are funded by investments. The company reported a net loss of $55.9 million for the year ended December 31, 2025. While Skye held $25.7 million in cash and short-term investments as of December 31, 2025, which is projected to sustain operations through the end of 2026 or Q1 2027, its cash burn significantly increased by 85% in the last twelve months. The company's cash burn relative to its market capitalization (139%) suggests a high risk of needing additional funding in the near future, which could lead to further stock dilution or financial distress if capital is not secured on favorable terms. A Piotroski F-Score of 2 also points to potential financial weaknesses.

3. Intense Competition in the Obesity Market

   Skye Bioscience's primary focus has shifted to developing nimacimab for the obesity market. This is a highly competitive landscape dominated by major pharmaceutical companies with established and effective GLP-1 receptor agonist therapies, such as Wegovy (semaglutide) from Novo Nordisk and Zepbound (tirzepatide) from Eli Lilly. While nimacimab aims to offer differentiated benefits, potentially as a combination therapy to enhance weight loss and address limitations of existing treatments, entering a market with such strong incumbents presents a substantial challenge. The market's reception to nimacimab as a monotherapy for weight loss has been poor, leading to a significant decline in share value, underscoring the difficulty of competing in this crowded field.

The addressable markets for Skye Bioscience's main products are detailed below:

SBI-100 (Glaucoma and Ocular Hypertension)

• Glaucoma: The global glaucoma treatment market was valued at USD 6.6 billion in 2024 and is projected to grow to USD 10.5 billion by 2034. The U.S. market for glaucoma treatment was approximately USD 2.24 billion in 2024, anticipated to grow to USD 3.96 billion by 2034.
• Ocular Hypertension: The global ocular hypertension market was valued at USD 5.1 billion in 2024 and is estimated to reach USD 7.2 billion by 2030. The U.S. ocular hypertension market is projected to expand from USD 1.78 billion in 2024 to USD 2.34 billion by 2030. The top 7 major markets (US, EU4, UK, and Japan) for ocular hypertension reached a value of USD 3,166.1 million in 2024, with projections to reach USD 4,752.8 million by 2035.

SBI-200 (Uveitis, Dry Eye Syndrome, Macular Degeneration, and Diabetic Retinopathy)

• Uveitis: The global uveitis treatment market size was approximately USD 768.5 million in 2024 and is estimated to grow to USD 1.5 billion by 2034. The U.S. uveitis treatment market is projected to reach USD 612.2 million by 2034.
• Dry Eye Syndrome: The global dry eye syndrome treatment market size was estimated at USD 6.29 billion in 2024 and is projected to reach USD 9.20 billion by 2030. North America held a significant share of the global dry eye syndrome treatment market, accounting for 42.7% of revenue in 2024.
• Macular Degeneration: The global macular degeneration treatment market is projected to grow from USD 14.19 billion in 2024 to USD 22.90 billion by 2030. North America is expected to dominate the global macular degeneration treatment market, with a 46.7% share in 2026.
• Diabetic Retinopathy: The global diabetic retinopathy market size is valued at USD 9.13 billion in 2024 and is projected to grow from USD 9.9 billion in 2025 to USD 17.37 billion by 2033. North America dominated the diabetic retinopathy market in 2024.

For Skye Bioscience (SKYE), the expected drivers of future revenue growth over the next 2-3 years are primarily centered on the advancement of its metabolic disease pipeline, particularly its lead product candidate, nimacimab, for obesity. The company has redirected its focus from ophthalmic programs to this area.

1. Advancement and successful clinical development of nimacimab for obesity: Positive outcomes from ongoing and planned clinical trials, such as the CBeyond Phase 2a expansion study (topline results expected in Q4 2026) and subsequent Phase 2b studies, will be crucial. Nimacimab has demonstrated significant weight loss benefits, especially in combination with semaglutide, positioning it as a promising candidate in the large and growing obesity market.

2. Strategic partnerships or licensing agreements for nimacimab: As a clinical-stage company with no current revenue, securing collaborations with larger pharmaceutical companies for the development and commercialization of nimacimab would provide substantial non-dilutive funding through upfront payments, milestone payments, and future royalties, directly contributing to revenue growth.

3. Development and potential out-licensing of the Antibody-Peptide Conjugate (APC) program: Skye Bioscience is advancing an innovative APC program that combines nimacimab's unique mechanism with GLP-1 receptor agonists in a single therapeutic. Preclinical proof-of-concept data for this platform have shown additive weight loss. Progress in this program could open new market opportunities or lead to lucrative licensing deals.

4. Expansion into the second-line obesity treatment market: Nimacimab is being developed to target second-line treatment opportunities in the obesity market, particularly in combination with GLP-1 therapies. Successful clinical differentiation and market penetration in this segment would enable Skye Bioscience to capture a significant share of a high-value patient population.